Gapping up
In reaction to earnings/guidance:
- VNET +20.2%, HPQ +5.5% (also increases dividend), JWN +5.1%, DE +1.7%, SITM +1.2% (raises 4Q20 revenue guidance), DOOO +1.2%, DELL +0.9%
Other news:
- YJ +45.2% (signs cooperative framework agreement with Douyin)
- MESA +14.8% (MESA enters into new contract with AAL to operate 40 CRJ-900s)
- RNLX +12.2% (Renalytix JV Kantaro Biosciences received Emergency Use Authorization from the FDA for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit) CASI +10% (Chairman/CEO disclosed the purchase of about 227K shares worth nearly $500K (transaction dates 11/20-11/23))
- RUHN +3.9% (receives "Going Private" proposal for $3.40 per ADS)
- BLCT +3.7% (to acquire Finka)
- ALT +2.9% (announces submission of investigational new drug application for AdCOVID a single-dose intranasal COVID-19 vaccine)
- VFF +1.5% (entered into supply agreement with Medical Cannabis by Shoppers)
- MRNA +1.4% (announces the European Commission's approval of advance purchase agreement for initial 80 mln doses of mRNA vaccine against COVID-19 (mRNA-1273))
Analyst comments:
- ATKR +3.6% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- KFY +2.5% (upgraded to Outperform from Neutral at Robert W. Baird)
- ZS +2.3% (upgraded to Outperform from Neutral at Credit Suisse)